Tag: paclitaxel-coated balloon
One-year data from SIRONA trial show similar results for sirolimus versus...
Data from the prospective, multicentre, investigator-initiated SIRONA randomised clinical trial demonstrated MagicTouch (Concept Medical) sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with...
Paclitaxel controversy: Yes, device restrictions did cause harm
“Unfortunately, we are doing worse for our patients today,” were the sobering thoughts of Eric Secemsky (Beth Israel Deaconess Medical Center, Boston, USA) during...
New data and heated debates set to spark controversy in CX...
“These will be important, salutary lessons. Should a controversy arise again involving a proven efficacious therapy, we now know that stopping access to that...
UK MHRA update: Paclitaxel-coated device increased mortality risk is withdrawn for...
Following a review, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has updated guidance on the use of paclitaxel-coated devices stating that such...
LINC 2020: Geographical “inconsistencies” cast doubt on paclitaxel mortality signal
Peter Schneider (San Francisco, USA) talks to BLearning Peripheral at LINC 2020 (Leipzig Interventional Course; 28–31 January 2020, Leipzig, Germany) about the relevance of dose relationship and geographical...
Benefit and risk: Meta-analysis draws a heterogeneous picture of drug-coated balloon...
Scientists of Jena University Hospital, Germany, conducted a meta-analysis sought to evaluate benefit and risk of paclitaxel-coated balloon angioplasty compared to plain old balloon...
No evidence of increased mortality with paclitaxel-based devices in German claim...
A real-world safety analysis of paclitaxel-based devices in peripheral arteries, recently published in the European Heart Journal, showed no evidence for increased mortality over...
Pooled analysis of four RCTs finds drug-coated balloons superior to plain...
A pooled analysis of four randomised controlled trials finds drug-coated balloon (DCB) angioplasty superior to plain angioplasty in patients with femoropopliteal artery disease, irrespective...
First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...
Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...
